Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

12.07 +0.23 (+1.94%)
Streaming Delayed Price Updated: 2:50 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,392,050
Open 12.02
Bid (Size) 12.06 (2)
Ask (Size) 12.07 (6)
Prev. Close 11.84
Today's Range 11.75 - 12.15
52wk Range 5.785 - 13.85
Shares Outstanding 157,749,490
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
 
Via Benzinga

Performance

YTD
+38.1%
+38.1%
1 Month
-0.3%
-0.3%
3 Month
+4.8%
+4.8%
6 Month
+58.6%
+58.6%
1 Year
+6.2%
+6.2%

More News

Read More
This Broadcom Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
OCUL Sales Drop 18%
Via The Motley Fool
OCULAR THERAPEUTIX INC (NASDAQ:OCUL) Reports Mixed Q2 2025 Earnings Amid Clinical Progress
Via Chartmill
Earnings Scheduled For August 5, 2025
Via Benzinga
What's Next: Ocular Therapeutix's Earnings Preview
Via Benzinga
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews
Via Benzinga
Carnival Posts Better-Than-Expected Earnings, Joins Liminatus Pharma, Coinbase Global, Uber And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Expectations For Ocular Therapeutix's Future
Via Benzinga
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings
Via Benzinga
Earnings Scheduled For May 5, 2025
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts
Via Benzinga
A Peek at Ocular Therapeutix's Future Earnings
Via Benzinga
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts
Via Benzinga
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
What 4 Analyst Ratings Have To Say About Ocular Therapeutix
Via Benzinga
Why Ocular Therapeutix Was Bumping Higher This Week
Via The Motley Fool
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Via Benzinga
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback
Via Stocktwits
Earnings Scheduled For March 3, 2025
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga

Frequently Asked Questions

Is Ocular Therapeutix, Inc. - Common Stock publicly traded?
Yes, Ocular Therapeutix, Inc. - Common Stock is publicly traded.
What exchange does Ocular Therapeutix, Inc. - Common Stock trade on?
Ocular Therapeutix, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocular Therapeutix, Inc. - Common Stock?
The ticker symbol for Ocular Therapeutix, Inc. - Common Stock is OCUL on the Nasdaq Stock Market
What is the current price of Ocular Therapeutix, Inc. - Common Stock?
The current price of Ocular Therapeutix, Inc. - Common Stock is 12.07
When was Ocular Therapeutix, Inc. - Common Stock last traded?
The last trade of Ocular Therapeutix, Inc. - Common Stock was at 10/20/25 02:50 PM ET
What is the market capitalization of Ocular Therapeutix, Inc. - Common Stock?
The market capitalization of Ocular Therapeutix, Inc. - Common Stock is 1.90B
How many shares of Ocular Therapeutix, Inc. - Common Stock are outstanding?
Ocular Therapeutix, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.